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vant role.
In conclusion, in a large cohort of thalassemia and sick-
le cell patients the use of gadopentate dimeglumine and
gadobutrolo in CMR seems to be safe and well tolerated,
with a risk comparable to the general population. These
data support the routine use of Gd chelates contrast
agents in MR and especially in CMR to detect myocardial
fibrosis/necrosis for diagnostic and clinical management
of thalassemia or sickle cell patients. However, gadolini-
um should be used with caution in patients with hemo-
globinopathies who have severe renal dysfunction.
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Platelet morphological changes in 2 patients
with von Willebrand disease type 3 caused by
large homozygous deletions of the von
Willebrand factor gene
Platelet morphological defects have previously been
described in von Willebrand disease type 2B (VWD2B),
we now describe that they may also occur in patients
with VWD3 lacking both platelet and plasma von
Willebrand factor (VWF). Electron microscopy (EM) and
immunofluorescence labeling (IF) were used to examine
platelets from two VWD3 patients with a homozygous
deletion involving VWF and TMEM16B genes. Platelet
size heterogeneity was seen in both patients, with an
unusual characteristic being the presence of a subpopula-
tion of long thin platelets. The additional detection of cir-
culating megakaryocytes and derived fragments suggests
that the absence of VWF can affect megakaryocy-
topoiesis.
VWF is essential to platelet function mediating adhe-
sion and shear-dependent thrombus formation on the
vessel wall.1 Yet relatively little is known about its role in
megakaryocytopoiesis. Macrothrombocytopenia is found
in about 30% of patients with von Willebrand disease
type 2B (VWD2B) and the fall in platelet count can be
severe.2 In some families, circulating platelet agglutinates
are present.2-5 VWD2B results from mutations in exon 28
of the VWF gene that lead to amino acid substitutions in
the VWF A1 domain. The result is a gain-of-function and
VWF multimers that spontaneously bind to glycoprotein
(GP)Ib on platelets. VWD type 3 (VWD3) is characterized
by severely decreased or absent expression of VWF
resulting from a variety of mutations or VWF gene dele-
tions that are sometimes accompanied by alloantibody
development.1,6,7
We have previously reported impaired megakaryocy-
topoiesis due to a precocious interaction between GPIbα
with newly synthesized VWF in MKs of a family with
VWD2B given by a R1308P mutation.3 In vitro studies per-
formed on MKs in culture have confirmed that pro-
platelet formation is inhibited by blockade of GPIb.8 In
continuing our investigations into the importance of
VWF for platelet production, we have now examined
platelet morphology for 2 patients with VWD3 caused by
a previously characterized homozygous 253-kbp deletion
involving VWF and TMEM16B.7 Neither patient pos-
sessed detectable VWF:Ag in either their plasma or
platelets and their bleeding scores2 were high (P1, 24; P2,
25). Their platelet counts at the time of study were
241×109/L (P1) and 149×109/L (P2) (control range 150-
300×109/L). 
Electron microscopy (EM) was used to examine platelet
morphology. Figure 1 (a-f) shows a wide range of platelet
size heterogeneity in both patients. Illustrated are
enlarged and sometimes rounded platelets with internal
membrane complexes and a heterogeneous α-granule
distribution (a,e). Enlarged α-granules were occasionally
observed. An unexpected finding was the presence of
very long thin structures (c, d) as these have not been
reported in VWD2B.2 The structure in (f) resembles more
a MK fragment. In morphometric studies, a minimum of
100 platelet sections of platelets were analyzed for each
subject and compared to the results obtained for 4 con-
trol donors. Platelet maximal and minimal diameters
were measured using the Software Image J (NIH,
Bethesda, MD, USA). Statistics were performed using
Student’s t test or Pearson’s χ2 test. Results showed that
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the mean maximal diameter was 3.3±0.8 µm for P1 and
3.5±1.6 µm for P2 (controls 2.7±0.5 µm, p=0.01), while
the minimum diameters were 1.4 ± 0.7 µm for P1 and
1.5±0.7 µm for P2 (controls 1.1±0.8 µm, p=0.02). A strik-
ing difference was the percentage of platelets with a
diameter greater than 3 µm; for P1 it was 66%, P2 57%
and for the controls 24% (p=0.001). 
The large size of some of the cells seen in EM prompt-
ed us to immunolabel frozen-thin sections9,10 with a mix-
ture of AP-2 (anti-αIIbβ3), Bx-1 anti-GPIbα and FMC25
(anti-GPIX) glycoproteins specific for the platelet and MK
lineage (Figure 2A). Cells with a large nucleus surround-
ed by cytoplasm containing granules were labeled with
the platelet-specific antibodies, clearly suggesting the
presence of circulating MKs (a). For comparison, a large
round platelet from the same patient is shown in (b)
while in (c) the structure resembles a detached MK frag-
ment; both are labeled by the anti-platelet antibodies.
Immunofluorescence labeling and confocal microscopy
was performed with the same MoAbs as described.11
Blood smears of the patients with VWD3 were compared
to those of controls. Figure 2B shows for P1 what may be
a MK fragment (a) while nuclei surrounded by remnant
portions of cytoplasm strongly positive for αIIbβ3 were
also seen (b, c). For the other patient with VWD3, size
heterogeneity was observed but nucleated αIIbβ3-labeled
cells were found less frequently (data not shown).
We have shown for the first time that platelet size and
morphology may also be abnormal in VWD3. These
results suggest that a complete absence of VWF (VWD3),
as well as enhanced VWF binding to GPIb (VWD2B), may
interfere with megakaryocytopoiesis. It is tempting to
suggest that in VWD3 some MKs fail to follow a normal
maturation or migration. The presence of very long thin
platelets suggests that the absence of VWF results in
modifications in the endgame of proplatelet formation
and platelet release. Nevertheless, the absence of VWF
does not give rise to a Bernard-Soulier-like giant platelet
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Figure 1. Platelet morphology in VWD3. A gallery of electron
micrographs (EM) of platelets from P1 and P2. EM was performed
according to our standard procedures.3 Note the presence of elon-
gated and sometimes very thin platelets. Nevertheless, size het-
erogeneity is considerable, and a round platelet with membrane
complexes (MC) is shown in (a) while a large granule (LG) is to be
seen in (b). A large round platelet is shown in (e); whereas a frag-
ment probably abnormally detached from an MK is shown in (f).
Bar=1 µm
Figure 2. Circulating MKs in VWD3. (A) Electron micrographs
showing immunogold labeling with a mixture of anti-αIIbβ3 and
anti-GPIba MoAbs of cells obtained from P1. A large multilobulat-
ed nucleus (N) surrounded by cytoplasm with α-granules is shown
in (a). Intracellular and surface labeling (arrow heads) for platelet
markers indicate that this cell belongs to the megakaryocytic lin-
eage. Labeling of a large round platelet (b), and a tentatively iden-
tified cytoplasmic MK fragment (panel c), is also shown. Bars=1
µm. (B) Immunofluorescence labeling of blood smears from the
VWD3 patients using the MoAb AP-2 specific for the αIIbβ3 com-
plex and DAP (nucleus). Results for VWD3 show cells of widely dif-
ferent size positive for αIIbβ3. In (b, c) the cells contain a nucleus
and the surrounding cytoplasm is very thin and irregular but heav-
ily labeled. Control platelets are shown for comparison in (d). 
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syndrome.9 Conceivably, the absence of VWF in VWD3
could result in the loss of a GPIb-dependent signaling
pathway that helps regulate MK maturation and/or pro-
platelet formation. While the platelet changes shown in
the VWD3 patients do not give rise to major thrombocy-
topenia, and as such may not add to the clinical pheno-
type of VWD3, they may intervene under stress condi-
tions such as during major bleeding when megakaryocy-
topoiesis is stimulated. It is to be emphasized that our 2
patients belong to a select subpopulation of VWD3 and
that the gene deletion extends to TMEM16B that encodes
a Ca2+-activated Cl- channel.12 While it is not currently
known if this gene is expressed in the MK-lineage, fur-
ther studies are merited on a much larger number of
VWD3 patients arising from a range of genetic defects to
define the role of VWF in finely regulating platelet pro-
duction. 
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